1′-cyano nucleoside analogs and uses thereof

Patent metadata

Field	Value
Publication number	US-12404289-B2
Application number	US-202318544561-A
Country	US
Kind code	B2
Filing date	Dec 19, 2023
Priority date	Jun 24, 2020
Publication date	Sep 2, 2025
Grant date	Sep 2, 2025

Abstract

Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

First claim

What is claimed is:

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

5. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical formulation comprising a pharmaceutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

7. A pharmaceutical formulation comprising a pharmaceutically effective amount of a compound of claim 5 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

8. A method of treating or preventing a viral infection in a human in need thereof, wherein the method comprises administering to the human the compound of claim 1 and wherein the viral infection is a coronavirus infection, pneumoviridae virus infection, picornaviridae virus infection, flaviviridae virus infection, filoviridae virus infection, orthomyxovirus infection, or paramyxoviridae virus infection.

9. The method of claim 8 , wherein the method comprises administering to the human at least one additional therapeut

Assignees

• Gilead Sciences Inc

Inventors

• Byun Daniel H
• Chun Byoung-Kwon
• Clarke Michael O
• Jansa Petr
• Kalla Rao V
• Koltun Dmitry
• Mackman Richard L
• Perry Thao D
• Siegel Dustin S
• Simonovich Scott P

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P31/12 Primary

  Antivirals · CPC title

• A61K31/675

  having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate · CPC title

• C07D487/04

  Ortho-condensed systems · CPC title

• C07F9/6561 Primary

  containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings · CPC title